Home/Ovid Therapeutics/Jennifer L. Bath
JL

Jennifer L. Bath

Senior Vice President, Head of Program and Alliance Management

Ovid Therapeutics

Ovid Therapeutics Pipeline

DrugIndicationPhase
OV329 / TAK-935 (Soticlestat)Dravet Syndrome, Lennox-Gastaut SyndromePhase 3
OV350Angelman Syndrome (potential)Preclinical
OV882Angelman SyndromePreclinical
OV815Undisclosed rare neurological targetDiscovery